Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1993 May;61(5):1682–1686. doi: 10.1128/iai.61.5.1682-1686.1993

Safety, stability, and efficacy of noncapsulated mutants of Actinobacillus pleuropneumoniae for use in live vaccines.

T J Inzana 1, J Todd 1, H P Veit 1
PMCID: PMC280751  PMID: 8478056

Abstract

Clonal, noniridescent mutants of Actinobacillus pleuropneumoniae serotypes 1 and 5 were isolated following chemical mutagenesis with ethyl methanesulfonate. The absence of any detectable capsule was confirmed by inhibition radioimmunoassay. There were no differences between the parent and mutant strains in lipopolysaccharide or protein electrophoretic profiles or in hemolytic activity. There was no detectable reversion to the encapsulated phenotype in vitro after passage in mice or pigs or in microporous capsules that were implanted subcutaneously in pigs for 6 weeks. The mutants were able to survive for more than 1 week in pigs following subcutaneous inoculation, which resulted in a strong immune response to whole cells and Apx toxins I and II. Intratracheal challenge of pigs with the serotype 5 mutant at a dose 1 log greater than the 50% lethal dose for the parent resulted in no clinical disease or lesions except in one pig that had slight pneumonia and pleuritis. Twenty-four hours after challenge, A. pleuropneumoniae could not be recovered from the respiratory tracts of any of the challenged pigs except for the one infected pig; this isolate remained noncapsulated. Immunization of pigs with one or both serotypes of noncapsulated mutants protected all pigs against clinical disease following intratracheal challenge with the virulent homologous or heterologous serotype. Nonimmunized control pigs and pigs immunized with a commercial bacterin died or had to be euthanized within 24 h of challenge. Thus, live noncapsulated mutants of A. pleuropneumoniae may provide safe and cost-effective protection against swine pleuropneumonia. These observations support the possibility that noncapsulated mutants of other encapsulated, toxin-producing bacteria may also prove to be efficacious live-vaccine candidates.

Full text

PDF
1682

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bossé J. T., Johnson R. P., Nemec M., Rosendal S. Protective local and systemic antibody responses of swine exposed to an aerosol of Actinobacillus pleuropneumoniae serotype 1. Infect Immun. 1992 Feb;60(2):479–484. doi: 10.1128/iai.60.2.479-484.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Devenish J., Rosendal S., Bossé J. T. Humoral antibody response and protective immunity in swine following immunization with the 104-kilodalton hemolysin of Actinobacillus pleuropneumoniae. Infect Immun. 1990 Dec;58(12):3829–3832. doi: 10.1128/iai.58.12.3829-3832.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Fedorka-Cray P. J., Huether M. J., Stine D. L., Anderson G. A. Efficacy of a cell extract from Actinobacillus (Haemophilus) pleuropneumoniae serotype 1 against disease in swine. Infect Immun. 1990 Feb;58(2):358–365. doi: 10.1128/iai.58.2.358-365.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Frey J., Nicolet J. Hemolysin patterns of Actinobacillus pleuropneumoniae. J Clin Microbiol. 1990 Feb;28(2):232–236. doi: 10.1128/jcm.28.2.232-236.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Higgins R., Larivière S., Mittal K. R., Martineau G. P., Rousseau P., Cameron J. Evaluation of a Killed Vaccine Against Porcine Pleuropneumonia Due to Haemophilus pleuropneumoniae. Can Vet J. 1985 Feb;26(2):86–89. [PMC free article] [PubMed] [Google Scholar]
  6. Inzana T. J., Clark G. F., Todd J. Detection of serotype-specific antibodies or capsular antigen of Actinobacillus pleuropneumoniae by a double-label radioimmunoassay. J Clin Microbiol. 1990 Feb;28(2):312–318. doi: 10.1128/jcm.28.2.312-318.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Inzana T. J., Ma J., Workman T., Gogolewski R. P., Anderson P. Virulence properties and protective efficacy of the capsular polymer of Haemophilus (Actinobacillus) pleuropneumoniae serotype 5. Infect Immun. 1988 Aug;56(8):1880–1889. doi: 10.1128/iai.56.8.1880-1889.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Inzana T. J., Mathison B. Serotype specificity and immunogenicity of the capsular polymer of Haemophilus pleuropneumoniae serotype 5. Infect Immun. 1987 Jul;55(7):1580–1587. doi: 10.1128/iai.55.7.1580-1587.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Inzana T. J., Todd J., Koch C., Nicolet J. Serotype specificity of immunological assays for the capsular polymer of Actinobacillus pleuropneumoniae serotypes 1 and 9. Vet Microbiol. 1992 Jun 15;31(4):351–362. doi: 10.1016/0378-1135(92)90127-f. [DOI] [PubMed] [Google Scholar]
  10. Inzana T. J., Todd J., Ma J. N., Veit H. Characterization of a non-hemolytic mutant of Actinobacillus pleuropneumoniae serotype 5: role of the 110 kilodalton hemolysin in virulence and immunoprotection. Microb Pathog. 1991 Apr;10(4):281–296. doi: 10.1016/0882-4010(91)90012-y. [DOI] [PubMed] [Google Scholar]
  11. Inzana T. J. Virulence properties of Actinobacillus pleuropneumoniae. Microb Pathog. 1991 Nov;11(5):305–316. doi: 10.1016/0882-4010(91)90016-4. [DOI] [PubMed] [Google Scholar]
  12. Kamp E. M., Popma J. K., Anakotta J., Smits M. A. Identification of hemolytic and cytotoxic proteins of Actinobacillus pleuropneumoniae by use of monoclonal antibodies. Infect Immun. 1991 Sep;59(9):3079–3085. doi: 10.1128/iai.59.9.3079-3085.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Ma J. N., Inzana T. J. Indirect enzyme-linked immunosorbent assay for detection of antibody to a 110,000-molecular-weight hemolysin of Actinobacillus pleuropneumoniae. J Clin Microbiol. 1990 Jun;28(6):1356–1361. doi: 10.1128/jcm.28.6.1356-1361.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Ma J., Inzana T. J. Rapid purification of a 110-kilodalton hemolysin of Actinobacillus pleuropneumoniae by monoclonal antibody-affinity chromatography. Am J Vet Res. 1992 Jan;53(1):59–62. [PubMed] [Google Scholar]
  15. Murchison H., Larrimore S., Curtiss R., 3rd Isolation and characterization of Streptococcus mutans mutants defective in adherence and aggregation. Infect Immun. 1981 Dec;34(3):1044–1055. doi: 10.1128/iai.34.3.1044-1055.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Nielsen R. Haemophilus parahaemolyticus serotypes. Pathogenicity and cross immunity. Nord Vet Med. 1979 Oct;31(10):407–413. [PubMed] [Google Scholar]
  17. Nielsen R. Haemophilus pleuropneumoniae serotypes--cross protection experiments. Nord Vet Med. 1984 Jul-Aug;36(7-8):221–234. [PubMed] [Google Scholar]
  18. Nielsen R. Pleuropneumonia of swine caused by Haemophilus parahaemolyticus. Studies on the protection obtained by vaccination. Nord Vet Med. 1976 Jul-Aug;28(7-8):337–348. [PubMed] [Google Scholar]
  19. Rosendal S., Boyd D. A., Gilbride K. A. Comparative virulence of porcine Haemophilus bacteria. Can J Comp Med. 1985 Jan;49(1):68–74. [PMC free article] [PubMed] [Google Scholar]
  20. Rosendal S., MacInnes J. I. Characterization of an attenuated strain of Actinobacillus pleuropneumoniae, serotype 1. Am J Vet Res. 1990 May;51(5):711–717. [PubMed] [Google Scholar]
  21. Rosendal S., Miniats O. P., Sinclair P. Protective efficacy of capsule extracts of Haemophilus pleuropneumoniae in pigs and mice. Vet Microbiol. 1986 Sep;12(3):229–240. doi: 10.1016/0378-1135(86)90052-0. [DOI] [PubMed] [Google Scholar]
  22. Sebunya T. N., Saunders J. R. Haemophilus pleuropneumoniae infection in swine: a review. J Am Vet Med Assoc. 1983 Jun 15;182(12):1331–1337. [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES